Less miscarriage in pregnancy following Tamoxifen treatment of infertile patients with luteal phase dysfunction as compared to clomiphene treatment.
To compare the efficacy and the reproductive outcomes of Tamoxifen (TMX) vs. clomiphene citrate (CC) treatment in infertile women with luteal phase dysfunction. Eighty-seven consecutive infertile women with luteal phase dysfunction were randomly assigned to two treatment groups as: group 1 (TMX followed by CC) and group 2 (CC followed by TMX). The medications administered in the initial and the subsequent cross-over phase were given for 4 to 6 cycles except in those patients who achieved pregnancy within the first three cycles of treatment. The rates of pregnancy, spontaneous abortion and live-birth were calculated for comparison. Demographic profile and the frequency of other infertility factors between the two groups were comparable. The pregnancy rates were similar between TMX and CC treatment (initial treatment phase: TMX, 50.0% vs. CC, 56.4%; subsequent treatment phase: CC, 33.3% vs. TMX, 47.1%), but the abortion rates were significantly lower (p < 0.05) in TMX treatments (initial treatment phase: 8.3% and subsequent treatment phase: 12.5%) than that of CC treatments (initial treatment phase: 22.7% and subsequent treatment phase: 62.5%). When the rates were calculated by pooling the patients according to the medication they received, the miscarriage rate was significantly lower (p < 0.05) if the patients conceived during the TMX treatment (9.4% vs. CC, 33.3%). Tamoxifen and clomiphene citrate seem to be similarly effective in achieving pregnancy in patients with luteal phase dysfunction. However, Tamoxifen therapy is associated with a lower incidence of spontaneous abortion; thus Tamoxifen may be the better choice for the therapy of infertile women with luteal phase dysfunction.